TAGLN2 is a candidate prognostic biomarker promoting tumorigenesis in human gliomas

Table 1 Correlation of TAGLN2 expression in human glioma patients with different clinicopathological features. P values were determined by the Chi-square and Fisher’s exact tests

Variable		TAGLN2 high expression	TAGLN2 low expression	p value
Age	≥45	234	91	<0.001
Age	<45	78	203	<0.001
Gender	Male	183	170	0.836
Gender	Female	129	124	0.836
KPS	≥80	154	151	0.005
KPS	<80	46	20	0.005
WHO grade	II	49	165	<0.001
	III	113	126
	IV	148	4
TCGA subtype	Neural	34	77	<0.001
	Proneural	65	173
	Classical	84	2
	Mesenchymal	93	3
IDH1 status	Mutant	103	324	<0.001
IDH1 status	Wild-type	225	8	<0.001
MGMT promotor	Methylated	171	304	<0.001
MGMT promotor	Unmethylated	132	29	<0.001
1p/19q	Codeletion	38	132	<0.001
1p/19q	Non-codeletion	290	202	<0.001
TERT expression	Not expressed	113	203	<0.001
TERT expression	Expressed	221	130	<0.001
ATRX status	Mutant	49	146	<0.001
ATRX status	Wild-type	276	186	<0.001

ISSN: 1756-9966